Completion of Cel-Sci's New Facility Signals That Long Awaited Phase III Trial is Imminent

• Press Release
• Source: BiomedReports.com
• On 7:15 am EDT, Monday October 26, 2009

LOS ANGELES--(BUSINESS WIRE)--BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, (NYSE AMEX:CVM) new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial.

Related Quotes

Symbol	Price	Change
CVM	1.23	0.00

{"s" : "cvm","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Multikine is the company's flagship immunotherapeutic head and neck cancer treatment and is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Because it required a very specific cold-fill process for manufacturing, the Phase III trials have been on hold as Cel Sci dedicated the majority of their time and resources to build the new best-in-class production facility.

Additionally, once the facility is validated, Cel Sci will become the only entity offering the 4°C cold fill on a contract basis, meaning the potential to bring in significant revenue as an added bonus does exist.

BioMedReports' Vinny Cassano was presented with a unique inside look at the company's new facility and a complete special report of his tour is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/14683-inside-cel-scis-new-multikine-production-facility.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com

BioMedReports.Com
M. Davila, Editor, +1-323-472-4480
info@biomedreports.com